Survodutide
Pending FDA approval
Manufactured by Boehringer Ingelheim · Subcutaneous injection
Avg Weight Loss
~19% body weight over 46 weeks at 4
Dosing
Once weekly
Brand Cost
Pricing not yet established
Compounded
N/A
How It Works
Survodutide is a dual agonist that activates both GLP-1 and glucagon receptors. GLP-1 activation reduces appetite, slows gastric emptying, and improves insulin secretion. Glucagon receptor activation increases energy expenditure, promotes hepatic fat oxidation, and enhances lipolysis. The combination aims to produce greater weight loss than GLP-1 alone by both reducing caloric intake and increasing caloric expenditure. The glucagon component also targets liver fat reduction, making it promising for MASH (metabolic dysfunction-associated steatohepatitis).
Dosing & Titration
Survodutide
Titration Protocol
Phase 3 trial protocol: Start at 0.6mg weekly, titrate up every 4 weeks through 2.4mg, 3.6mg, 4.8mg to a maintenance dose of 6.0mg weekly (titration period approximately 20 weeks).
Common Side Effects
Serious Risks
Pancreatitis (theoretical class risk)
Increased heart rate
Hepatic effects (being monitored in trials)
Hypoglycemia
GI side effects leading to dehydration
Full safety profile still under investigation
Cost Comparison
Brand Name
Pricing not yet established
per month
Compounded
N/A
per month
Pharmacy Options
Not yet available
Insurance Coverage
Not yet applicable. Expected to seek FDA approval for both obesity and MASH indications.
Pros & Cons
Advantages
- Dual mechanism increases energy expenditure (not just appetite suppression)
- Strong MASH/liver fat reduction data — unique among GLP-1 class
- Once-weekly dosing
- Competitive weight loss approaching tirzepatide levels
- Addresses metabolic liver disease — large unmet need
Disadvantages
- Not yet FDA approved
- Glucagon activation may raise blood glucose (offsetting GLP-1 glucose-lowering)
- GI side effects appear comparable to other GLP-1 agents
- Long titration period (~20 weeks to max dose)
- Limited long-term safety data
Clinical Evidence
Clinical Trial Programs
SYNCHRONIZE program: SYNCHRONIZE-1 (obesity without diabetes), SYNCHRONIZE-2 (obesity with Type 2 Diabetes), SYNCHRONIZE-3 (MASH with fibrosis). Phase 2 results published in NEJM (2024).
phase2Obesity
Up to 19.0% weight loss at 4.8mg over 46 weeks vs 2.1% placebo. 44% of participants lost >=20% body weight.
phase2MASH
Up to 83% MASH resolution rate (vs 18.2% placebo) in Phase 2b MASH trial
Contraindications
- Not yet approved — contraindications will be determined through regulatory review
- Likely to include MTC/MEN 2 history (consistent with GLP-1 class)
Find providers offering Survodutide near you
Compare pricing, pharmacy sourcing, and clinical oversight across verified providers prescribing Pending FDA approval.
Get weekly GLP-1 medication updates
New research, pricing changes, and provider comparisons — delivered to your inbox.
No spam. Unsubscribe anytime.
Compare all GLP-1 medications
See how Survodutide stacks up against other GLP-1 options. Compare efficacy, cost, side effects, and dosing schedules side by side.